PRO-RESOLVING SKIN INFLAMMAGING

Our pack of efficacy studies are focused on showing the benefits of Bicoalgae $\omega 3$ in improving three typical situations related with skin inflammaging:

1. PRESENCE OF PRO-INFLAMMATORY CYTOKINES IN SKIN TISSUE (skin explants)

The decrease of age-related inflammatory cytokine 1L- 1 β and IL-8 in inflammed skin explants were evaluate post treatment with Bicoalgae® ω 3.

2. SKIN OXIDATIVE STRESS FROM EXPOSURE TO ELECTRONIC DEVICES and UV-VIS radiation (skin explants)

Bicoalgae® $\omega 3$ capacity to decrease oxidative inflammatory states related to exposure to Blue light from electronic devices and UV-Vis radiation in different skin layers.

3. CHRONIC INFLAMMATORY DISORDER (in vivo).

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days. The measurements were carried out at 0 and 30 days under Dermatological control.






DECREASE OF PRO INFLAMMATORY CYTOKINES

in vitro Inflamed skin explants

The constant release of ROS and pro-inflammatory cytokines characterise skin chronic inflammation.

The decrease of pro-inflammatory cytokines in inflamed tissues indicate improvement of inflammaging.



Bicoalgae® ω3 decreases the level of the age-related proinflammatory cytokine IL-1β in inflammed skin

Average result of concentration of IL $-\beta 1$ in skin samples (n=4).

Experiment procedure:


To evaluate the effect of Bicoalgae- ω 3 in reducing pro-inflammatory cytokines, levels of IL-1 β were measured in inflamed organotypic cultures of human skin explants treated and non-treated with Bicoalgae- ω 3 (1% and 3%). Human skin explants were treated with the compounds in the presence of bacterial Lipopolysaccharides (LPS), simulating a generic skin inflammation. The cytokines IL-1 β were calculated after 24 hours of incubation.



DECREASE OF PRO INFLAMMATORY CYTOKINES

in vitro Inflamed skin explants

The possibility that circulating pro-inflammatory cytokines in inflammaging are being originated in the skin is now being explored by several research groups around the world. ⁶ Evidence of this would change forever the way we treat our skin.



Bicoalgae® ω3 decreases the level of age-related proinflammatory citokine IL-8 in inflammed skin

Average result of concentration of IL -8 in skin samples (n=4).

Experiment procedure:

To evaluate the effect of Bicoalgae- ω 3 in reducing pro-inflammatory cytokines, levels of IL-8 were measured in inflamed organotypic cultures of human skin explants treated and non-treated with Bicoalgae- ω 3 (1% and 3%). Human skin explants were treated with the compounds in the presence of bacterial Lipopolysaccharides (LPS), simulating a generic skin inflammation. The cytokines IL-8 were calculated after 24 hours of incubation.




6. Ye et al. (2019). Topical applications of an emollient reduce circulating pro-inflammatory cytokine levels in chronically aged humans: a pilot clinical study.

BLUE LIGHT PROTECTION


in vitro skin explants

Exposure to blue light radiation (λ = 400-500 nm) from **electronic devices**, **fluorescent and LED lights** generates an excess of ROS that favours chronic inflammatory states in the skin.


Control Not irradiated Not treated



Control
Blue light irradiated
Not treated




Blue light irradiated Treated with Bicoalgae ω3



Visualization of ROS in fluorescent marked skin explants (A) not irradiated and not treated, (B) irradiated and not treated and (C) irradiated and treated with Bicoalgae® ω3. Green fluorescence indicates presence of ROS.

QUANTIFICATION OF ROS IN THE SKIN



Bicoalgae[®] ω3 prevents the generation ROS blue light induced

Experiment procedure:


Skin samples treated and non treated with a cream containing 3% of Bicoalgae® ω 3 for 24h were incubated during 30 min with dichlorofluorescein diacetate (DCFH-DA) at 40°C. DCFH-DA is a fluorescent marker that reacts with ROS becoming fluorescent.

Afterwards the skin samples were irradiated with blue light (λ = 468nm) during 4h. Control and test samples were observed by optical microscopy using fluorescence filters to evidence the presence of ROS and quantify them.



OXIDATIVE STRESS UV – VIS INDUCED

in vitro skin explants




Bicosome® increase the efficacy of the microalgae extracts in the SC, Epidermis and Dermis

Experiment procedure:

First, skin samples treated with a cream containing 3% of Bicoalgae ω 3 (B0) or the microalgae extracts (M0) and incubated for 24h. Afterwards, skin samples treated with B0 and M0 creams and non treated samples were incubated during 30 min with dichlorofluorescein diacetate (DCFH-DA) at 40°C. DCFH-DA is a fluorescent marker that reacts with R0S becoming fluorescent. Finally, the skin samples were irradiated with UV-VIS using a SUNTEST CPS (Atlas, Illinois, USA) at 500 W/m2 during 30 min. Positive and negative controls and test samples were observed by optical microscopy using fluorescence filters to evidence the presence of R0S and quantify them.

NORMALISATION OF SKIN BARRIER FUNCTION

in vivo 20 volunteers inflamed skin condition



Normal

condition

Average decrease transepidermal water loss at different experimental times (n=20, p value =0.000).

Experiment procedure:

26

25

24

23

Normal condition

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω3 at 3% twice a day, morning and evening, during 30 days.

Day 30

Transepidermal water loss (TEWL) was evaluated on the volunteer's forehead with the equipment Tewameter® TM 300 at the beginning and the end of the treatment..




from pathological levels to normal levels.

Day 0

MELANIN REDUCTION

in vivo 20 volunteers inflamed skin condition

Age spots are characteristic of chronic inflamed skin. The chronic state of inflammation can affect the function of melanocytes causing this age-related condition.⁶



Average result of Mexameter value in different experimental times (n=20, * = p value = 0.05).



Bicoalgae[®] ω3 cream improved hyperpigmented spots

Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days. Melanin content was measured using a Mexameter at the beginning and the end of the treatment.




Reference:

6.Zhuan & Lyga, 2014. Inflammaging in Skin and Other Tissues – The roles of Complement System and Macrophage. Inflammatin & Allergy – Drug targets, 13, 153 – 161.

3D ANALYSIS BY VISIA® TECHNOLOGY

in vivo 20 volunteers inflamed skin condition

Quantification of red spots, sunspots, pores and porphyrins give valuable information in the analysis of the improvement of inflammatory conditions.





Bicoalgae® ω3 cream decreased number of surface bacteria, pores and skin spots.


Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω_3 at 3% twice a day, morning and evening, during 30 days. Visia® was used to evaluate changes in skin color hyperpigmentation (freckles, melasma), red areas (vascular disorders due to acne, rosacea, spider veins, inflammation, presence of large pores and porphyrins, at the begining and and the end of the study.



INVESTIGATOR GLOBAL ASESSMENT - IGA

in vivo 20 volunteers inflamed skin condition





Bicoalgae® $\omega 3$ cream improved volunteers inflammatory condition around 35.1% according with clinical evaluation.


Experiment procedure:


Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω_3 at 3% twice a day, morning and evening, during 30 days. The Dermatologist evaluate volunteers using IGA scale.



DECREASE OF ACNE LESIONS

in vivo 20 volunteers inflamed skin condition





Average score of Dermatologist based on IGA score (n=20). p value = 0.022 for blackheads and p value = 0.035 for whiteheads

The use of the **Bicoalgae®** ω3 cream decreased relevantly both white and blackhead lesions.

Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days.

The Dermatologist evaluated comedogenicity by counting white and blackhead lesions before and after treatment.



PATIENT GLOBAL ASESSMENT - PGA

in vivo 20 volunteers inflamed skin condition

PGA is a measurement instrument for patient subjective evaluation on the perception evolution of its condition. It uses a punctuation systems that goes from -2 (meaning relevant worsening) to + 3 (meaning intense improvement).

Average improvement 1.4 *

Bicoalgae® ω3 cream raised volunteers perception on the improvement of their inflammatory condition.

Average score of PGA score (n=20).

p value = 0.001

Experiment procedure:


Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days. The patients evaluated their condition together with the Dermatologist using PGA scale.





PATIENT EFFICACY SELF - ASSESSMENT

Additionally, patients weekly evaluated the improvement of their main inflammatory symptoms.









Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days.

Volunteers answered a questionnaire using a scale from 0 to 5, where 0 strongly disagrees and 5 strongly agrees to evaluate stinging, irritation, dryness and general improvement of the treatment at different days during the study.






SELF ASSESSMENT USE TEST

in vivo 20 volunteers inflamed skin condition

Volunteers rated **Bicoalgae®** ω3 cream sensorial impact in their skin



Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω 3 at 3% twice a day, morning and evening, during 30 days.


Weekly volunteers answered a questionnaire to evaluate the sensorial impact of the formula in their skin.



PRODUCT COSMETICITY USE TEST

in vivo 20 volunteers inflamed skin condition

Volunteers also evaluated $Bicoalgae^{\otimes} \omega 3$ cream cosmeticity.




Experiment procedure:

Twenty (20) adult volunteers, average age of 36 years old, with chronic mild to moderate inflammatory acne and/or rosacea used a cream containing Bicoalgae® ω_3 at 3% twice a day, morning and evening, during 30 days.

Weekly volunteers answered a questionnaire to evaluate the product cosmeticity.







SUMMARY OF RESULTS

- ightharpoonup Decreases the level of the age-related cytokines IL-1β and IL-8 in inflamed skin models.
- Prevents the generation of ROS induced by blue light.

BICOALGAE® ω3 is a SUPER SKIN FOOD that works proving microalgae EPA and DHA rich extracts deep in the skin

- The incorporation of the MO extracts in Bicoalgae® ω3 increased their efficacy in reducing ROS in the Stratum Corneum, Epidermis and Dermis.
- The clinical study showed 35% improvement in volunteers general inflammatory condition in 30 days. The use of B0 cream reduced TEWL, hyperpigmented lesions, surface bacteria, pores and skin red and sun spots.
- Volunteers self assessment showed good perception in the improvements of stinging, redness, dryness, skin texture, smoothness, brightness and hydration. Volunteers also approved product cosmeticity and sensoriality.

bicosome®